India, April 8 -- Two newly published studies have found that GLP-1 receptor agonists drugs such as Ozempic, Trulicity, and Victoza, may significantly reduce the risk of developing dementia.
In the first study, published in JAMA Neurology, researchers explored the potential impact of GLP-1 receptor agonists (semaglutide, dulaglutide, and liraglutide) on dementia risk among individuals with type 2 diabetes.
They also assessed the effects of another class of diabetes drugs, SGLT2 inhibitors, including empagliflozin (Jardiance) and dapagliflozin (Farxiga).
The research analyzed health records from 396,963 adults over the age of 50 with type 2 diabetes, using data from the OneFlorida+ Clinical Research Consortium spanning January 2014 to Jun...